Trending Now

Biopharma Gains Another Shot on Goal With IND Approval

Research Report

Edward White (01/26/2023)

The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Former Investment Officer of One of the World's Largest Sovereign Wealth Funds Shares His Current Focus

Streetwise Reports (01/25/2023)

Streetwise Reports sat down with Øyvind Schanke, the chief investment officer of TD Veen and the former investment officer of one of the world's largest sovereign wealth funds as he shares his current focus.

Tags: Life Sciences Tools & Diagnostics

Med Tech Co. Well-Poised for Revenue Growth This Year

Research Report

Swayampakula Ramakanth (01/25/2023)

New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report.

Tags: Medical Devices

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment

Streetwise Reports (01/24/2023)

This morning Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

Biopharma Creating COVID Drug Gets US$8.2M From the DOD

Research Report

Edward White (01/24/2023)

This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Exploring Why The Economist Named this Biotech 'One To watch' in 2023

Streetwise Reports (01/23/2023)

As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023.

Tags: PsychedelicsHealthcare ServicesBiotechnology / Pharmaceuticals

Telehealth Co. Expects More Growth in 2023

Streetwise Reports (01/20/2023)

Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023, which could lead to a share buyback program.

Tags: Life Sciences Tools & DiagnosticsTechnologyHealthcare Services

Biopharma Co.'s Burn Tissue Removal Product Approved

Research Report

Swayampakula Ramakanth (01/04/2023)

Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.

Tags: Biotechnology / Pharmaceuticals

Which Precious Metal Has Chen Excited for 2023?

Streetwise Reports (12/28/2022)

It's valued the world over as a precious metal, and now it's in demand for the green economy. Which element has asset manager Chen Lin looking forward to the New Year?

Tags: Critical MetalsSilverBiotechnology / PharmaceuticalsOil & Gas - ServicesOil & Gas - Exploration & Production

Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio

Contributed Opinion

Clive Maund (12/28/2022)

Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.

Tags: Biotechnology / Pharmaceuticals

Target Price Boosted 400% on Biopharma Co.

Research Report

Dr. Joseph Pantginis (12/27/2022)

The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Biotech at Good Entry Point for Investors, Analyst Says

Research Report

Andrew Partheniou (12/20/2022)

The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.

Tags: Psychedelics

Data on New Cell Therapy for LBCL Encouraging, Analyst Says

Research Report

Justin Zelin (12/16/2022)

The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report.

Tags: Regenerative Medicine

Why One Fund Owns 13% of This Small-Cap Pharma

Streetwise Reports (12/12/2022)

Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

Biotech Co. Signs US$735M Deal

Streetwise Reports (12/09/2022)

Entrada Therapeutics Inc. shares traded 18.5% higher yesterday after the company reported it entered a global development collaboration with Vertex Pharmaceuticals Inc. to develop cutting-edge intracellular Endosomal Escape Vehicle (EEV™) therapeutics for use in treating myotonic dystrophy type 1.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Shares Soar to New 52-Week High

Streetwise Reports (12/07/2022)

Prometheus Biosciences Inc. shares traded 170% higher to a new 52-week intraday high after the company reported positive results from two separate Phase 2 clinical studies for its PRA023, an anti-TL1A mAb used to treat inflammatory bowel disease. The company is actively planning to advance PRA023 into Phase 3 trials as a prospective treatment for ulcerative colitis and Crohn's disease in FY/23.

Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

"RHT's balance sheet rating improved during Q1/23."

–Jefferson Research

"AGN plans to initiate a Phase 2b trial of ifenprodil in chronic cough."

–Douglas Loe, Leede Jones Gable

"We expect PMN to commence formal Phase 1 testing later this year."

–Douglas Loe, Leede Jones Gable

"When AGN moves, it is likely to result in big percentage gains."

–Clive Maund, CliveMaund.com

"The valuation for RHT suggests a lower amount of price risk."

–Jefferson Research

"Data presented by peers at the CTAD conference are relevant to PMN."

–Douglas Loe, Leede Jones Gable

"Positive Phase 2a data were achieved with AGN's ifenprodil."

–Dr. André Uddin, Research Capital Corporation

"This is a good point to add to positions or make new purchases of RHQ."

–Clive Maund, CliveMaund.com

"RHT added 50 new nursing home clients in Florida to its network."

–Douglas Loe, Leede Jones Gable

"The dip of recent days presents us with a better entry point for RHT."

–Clive Maund, CliveMaund.com

"PMN expects to file an NDA for PMN310 with the FDA by 2022E."

–Steve Silver, Argus Research

"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com

"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com

"This is a good time to buy PMN stock."

–Clive Maund, CliveMaund.com

"PMN peer, Eisai, reported positive Phase 3 Alzheimer's disease data."

–Douglas Loe, Leede Jones Gable

"We are positive about PMN's PMN-310 possibly mitigating AD progression."

–Douglas Loe, Leede Jones Gable

"A minor relief rally in the broad market could see AGN shoot up again."

–Clive Maund, CliveMaund.com

"The case for buying AGN here could scarcely be stronger."

–Clive Maund, CliveMaund.com

"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com

"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com

More News ACET:NASDAQ | IKT:NASDAQ

Company News

RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN
1/27/2023 – Reliq Health Technologies, Inc. Announces 30 New Skilled Nursing Facility Clients in FL and a New Contract with a Large Clinic in TX

RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN
1/25/2023 – Reliq Health Technologies, Inc. to Participate in the Lytham Partners Investor Select Conference

AWKN:NEO; AWKNF:OTCQB
1/24/2023 – Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect

Streetwise Key Charts

Pharma Biotech & Life Sci

Tune In to Our NEW Podcast: Streetwise Listens

Biopharma Co.'s Shares Triple in Value on US$5B License Deal

Streetwise Reports (12/07/2022)

Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-license agreement with Akeso Inc. for its breakthrough bispecific antibody ivonescimab, which combines a blockade of PD-1 with an anti-VEGF into a single molecule designed to target cancer. Summit has agreed to pay Akeso an upfront payment of US$500 million, which it plans to finance via an equity rights issuance.

Tags: Biotechnology / Pharmaceuticals

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial

Streetwise Reports (12/05/2022)

Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline.

Tags: Biotechnology / Pharmaceuticals

Target Price Boosted on Canadian Pharma Co.

Research Report

Dr. Andre Uddin (11/30/2022)

This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals